NCT05117710 - IMPase in Treatment-resistant Depression | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 22, 2021

Primary Completion Date

May 31, 2024

Study Completion Date

May 31, 2024

Conditions

Depressive Disorder, Treatment-Resistant

Interventions

DRUG

Ebselen

Ebselen is an organoselenium compound, developed originally as an antioxidant for use in neuroprotection, post-stroke. Ebselen is a bioavailable and brain penetrant inhibitor of inositol monophosphatase (IMPase) (Ki ≈ 1 μM).

DRUG

Placebo

Matched placebo capsules

Trial Locations (1)

OX37JX

RECRUITING

Neurosciences Building, Dept. Psychiatry, Warneford Hospital, Oxford